|
Re: Warning: Long - Thoughts on Management
|
3
|
Resverlogix Corp.
|
Mar 24, 2021 09:01PM
|
|
Re: Video presentation from August 25, 2021
|
4
|
Resverlogix Corp.
|
Aug 31, 2021 05:45PM
|
|
Re: Video presentation from August 25, 2021
|
5
|
Resverlogix Corp.
|
Aug 31, 2021 06:58PM
|
|
Re: Video presentation from August 25, 2021
|
6
|
Resverlogix Corp.
|
Aug 31, 2021 07:15PM
|
|
Re: Video presentation from August 25, 2021
|
4
|
Resverlogix Corp.
|
Aug 31, 2021 07:50PM
|
|
Re: Video presentation from August 25, 2021
|
7
|
Resverlogix Corp.
|
Aug 31, 2021 10:14PM
|
|
Re: Video presentation from August 25, 2021
|
7
|
Resverlogix Corp.
|
Aug 31, 2021 11:03PM
|
|
Re: Update
|
3
|
Resverlogix Corp.
|
Dec 16, 2021 05:16PM
|
|
Re: Update
|
8
|
Resverlogix Corp.
|
Dec 17, 2021 09:00PM
|
|
Re: Thoughts on Votes
|
5
|
Resverlogix Corp.
|
Jul 01, 2023 07:04PM
|
|
Re: someone doesn’t believe in rumours…
|
|
Zenith Epigenetics
|
Dec 08, 2023 02:49PM
|
|
Re: So, the mood this week was.
|
4
|
Resverlogix Corp.
|
Aug 25, 2021 03:48PM
|
|
Re: So, the mood this week was.
|
5
|
Resverlogix Corp.
|
Aug 26, 2021 11:24AM
|
|
Re: RVX- Exempt Distribution
|
4
|
Resverlogix Corp.
|
Apr 01, 2022 06:37PM
|
|
Re: Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
|
1
|
Resverlogix Corp.
|
Jul 31, 2024 08:38PM
|
|
Re: Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
|
1
|
Resverlogix Corp.
|
Sep 08, 2021 06:55PM
|
|
Re: Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
|
1
|
Resverlogix Corp.
|
Sep 08, 2021 07:54PM
|
|
Re: Reports of Exempt Distribution
|
1
|
Zenith Epigenetics
|
Feb 06, 2023 11:59AM
|
|
Re: Presentation
|
1
|
Resverlogix Corp.
|
Oct 05, 2021 03:30PM
|
|
Re: New Covid mutation on the radar -- 'Mu'
|
4
|
Resverlogix Corp.
|
Sep 01, 2021 01:34PM
|
